Figure 1.

(A) The figure shows the changes in the FEV₁ during three different periods. In the first period, the patient was receiving omalizumab, in the second mepolizumab, and in the third, mepolizumab and omalizumab. Note the marked improvement in the FEV₁ during the dual mAb therapy. (B) The values of oral corticosteroid are the mean monthly accumulated intake during the treatment period of the last year of omalizumab alone, the 14 months on mepolizumab and the 24 months on omalizumab plus mepolizumab. A clear trend towards a decrease in oral corticosteroid consumption was observed. During the last three months, the daily OC dose was 2.5 mg/day.